Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Dermatol. 2011 Aug;165(2):411-4. doi: 10.1111/j.1365-2133.2011.10402.x.

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.

Author information

1
Department of Dermatology, Safdarjung Hospital Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi 110029, India. weramesh@hotmail.com

Abstract

BACKGROUND:

  Post-kala-azar dermal leishmaniasis (PKDL) constitutes a parasite reservoir important in the transmission of visceral leishmaniasis (VL). Unacceptable treatment regimens and increasing drug resistance blight control programmes. The success of oral miltefosine in VL prompted a clinical, histopathological and parasitological study of this drug in PKDL.

OBJECTIVES:

To define the dose and duration of miltefosine for treatment of PKDL.

METHODS:

Twenty-six patients confirmed by slit-skin smear, histopathology and molecular tests were enrolled in the study. They received miltefosine capsules 50 mg thrice daily after food. Treatment was for 60 days with a provision to increase by 30 days if a responder had not attained a cure. Cure was ascertained by clinical and histopathological examination, and measuring parasite burden using real-time polymerase chain reaction.

RESULTS:

Twenty-four patients with a wide range of parasite burden completed the study. Twenty-three achieved a cure giving an initial cure rate of 96% (95% confidence interval 79-99%). Sixteen patients were cured with 50 mg thrice daily, 13 in 60 days and three within 90 days. In seven cases, miltefosine had to be reduced, because of gastrointestinal intolerance, to 50 mg twice daily to a total of 180 capsules. Lesional parasites were undetectable at 1 month post-treatment. Treatment was safe with no relapses at 1-year follow-up.

CONCLUSION:

Oral miltefosine, 50mg thrice daily for 60 days or twice daily for 90 days, could be an effective treatment for PKDL.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center